These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 35563753)
1. B7-H4 Immune Checkpoint Protein Affects Viability and Targeted Therapy of Renal Cancer Cells. Emaldi M; Nunes-Xavier CE Cells; 2022 Apr; 11(9):. PubMed ID: 35563753 [TBL] [Abstract][Full Text] [Related]
2. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma. Fukuda T; Kamai T; Masuda A; Nukui A; Abe H; Arai K; Yoshida K Cancer Med; 2016 Aug; 5(8):1810-20. PubMed ID: 27292320 [TBL] [Abstract][Full Text] [Related]
3. Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors. Chen D; Li G; Ji C; Lu Q; Qi Y; Tang C; Xiong J; Hu J; Yasar FBA; Zhang Y; Hoon DSB; Yao Y; Zhou L J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457124 [TBL] [Abstract][Full Text] [Related]
4. Mifepristone inhibited the expression of B7-H2, B7-H3, B7-H4 and PD-L2 in adenomyosis. Qin X; Sun W; Wang C; Li M; Zhao X; Li C; Zhang H Reprod Biol Endocrinol; 2021 Jul; 19(1):114. PubMed ID: 34289871 [TBL] [Abstract][Full Text] [Related]
5. Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. Genova C; Tasso R; Rosa A; Rossi G; Reverberi D; Fontana V; Marconi S; Croce M; Dal Bello MG; Dellepiane C; Tagliamento M; Ciferri MC; Zullo L; Fedeli A; Alama A; Cortese K; Gentili C; Cella E; Anselmi G; Mora M; Barletta G; Rijavec E; Grossi F; Pronzato P; Coco S Cells; 2023 Mar; 12(6):. PubMed ID: 36980174 [TBL] [Abstract][Full Text] [Related]
6. Multiplexed Spatial Imaging at the Single-Cell Level Reveals Mutually Exclusive Expression of B7 Family Proteins. Shojo K; Tanaka N; Murakami T; Anno T; Teranishi Y; Takamatsu K; Mikami S; Imamura T; Matsumoto K; Oya M Lab Invest; 2024 Oct; 104(10):102131. PubMed ID: 39244158 [TBL] [Abstract][Full Text] [Related]
7. Clinical significance and correlation of PD-L1, B7-H3, B7-H4, and TILs in pancreatic cancer. Yang J; Tian Z; Gao H; Xiong F; Cao C; Yu J; Shi W; Zhan Q; Yang C BMC Cancer; 2022 May; 22(1):584. PubMed ID: 35624419 [TBL] [Abstract][Full Text] [Related]
8. Clinical significance of blocking novel immune checkpoint B7-H4 in urothelial carcinoma of bladder as a potential therapeutic target. Raja D; Singh A; Kurra S; Nayak B; Kaushal S; Sharma A; Singh P Med Oncol; 2024 Feb; 41(3):74. PubMed ID: 38376603 [TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer. Nunes-Xavier CE; Kildal W; Kleppe A; Danielsen HE; Waehre H; Llarena R; Maelandsmo GM; Fodstad Ø; Pulido R; López JI Prostate; 2021 Sep; 81(12):838-848. PubMed ID: 34125445 [TBL] [Abstract][Full Text] [Related]
10. B7-H3 immune checkpoint expression is a poor prognostic factor in colorectal carcinoma. Lu Z; Zhao ZX; Cheng P; Huang F; Guan X; Zhang MG; Chen HP; Liu Z; Jiang Z; Zheng ZX; Zou SM; Wang XS Mod Pathol; 2020 Nov; 33(11):2330-2340. PubMed ID: 32514163 [TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint molecules B7-H6 and PD-L1 co-pattern the tumor inflammatory microenvironment in human breast cancer. Cherif B; Triki H; Charfi S; Bouzidi L; Kridis WB; Khanfir A; Chaabane K; Sellami-Boudawara T; Rebai A Sci Rep; 2021 Apr; 11(1):7550. PubMed ID: 33824367 [TBL] [Abstract][Full Text] [Related]
12. B7-H4 correlates with clinical outcome and immunotherapeutic benefit in muscle-invasive bladder cancer. Liu Z; Jin K; Zeng H; Shao F; Chang Y; Wang Y; Xu L; Wang Z; Cui X; Zhu Y; Xu J Eur J Cancer; 2022 Aug; 171():133-142. PubMed ID: 35717821 [TBL] [Abstract][Full Text] [Related]
13. High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation. MacGregor HL; Sayad A; Elia A; Wang BX; Katz SR; Shaw PA; Clarke BA; Crome SQ; Robert-Tissot C; Bernardini MQ; Nguyen LT; Ohashi PS J Immunother Cancer; 2019 Dec; 7(1):357. PubMed ID: 31892360 [TBL] [Abstract][Full Text] [Related]
14. Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC. Thomas PL; Groves SM; Zhang YK; Li J; Gonzalez-Ericsson P; Sivagnanam S; Betts CB; Chen HC; Liu Q; Lowe C; Chen H; Boyd KL; Kopparapu PR; Yan Y; Coussens LM; Quaranta V; Tyson DR; Iams W; Lovly CM J Thorac Oncol; 2021 Jul; 16(7):1211-1223. PubMed ID: 33839362 [TBL] [Abstract][Full Text] [Related]
15. The role of B7-H4 in ovarian cancer immunotherapy: current status, challenges, and perspectives. Zhou L; Duan Y; Fu K; Zhang M; Li K; Yin R Front Immunol; 2024; 15():1426050. PubMed ID: 39267740 [TBL] [Abstract][Full Text] [Related]
16. B7 Family Members in Lymphoma: Promising Novel Targets for Tumor Immunotherapy? Zhang W; Qiu Y; Xie X; Fu Y; Wang L; Cai Z Front Oncol; 2021; 11():647526. PubMed ID: 33869045 [TBL] [Abstract][Full Text] [Related]
17. The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment. Bolandi N; Derakhshani A; Hemmat N; Baghbanzadeh A; Asadzadeh Z; Afrashteh Nour M; Brunetti O; Bernardini R; Silvestris N; Baradaran B Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639059 [TBL] [Abstract][Full Text] [Related]
18. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes. Altan M; Pelekanou V; Schalper KA; Toki M; Gaule P; Syrigos K; Herbst RS; Rimm DL Clin Cancer Res; 2017 Sep; 23(17):5202-5209. PubMed ID: 28539467 [No Abstract] [Full Text] [Related]
19. B7 family protein glycosylation: Promising novel targets in tumor treatment. Xiao L; Guan X; Xiang M; Wang Q; Long Q; Yue C; Chen L; Liu J; Liao C Front Immunol; 2022; 13():1088560. PubMed ID: 36561746 [TBL] [Abstract][Full Text] [Related]
20. Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. Genova C; Boccardo S; Mora M; Rijavec E; Biello F; Rossi G; Tagliamento M; Dal Bello MG; Coco S; Alama A; Vanni I; Barletta G; Bianchi R; Maggioni C; Bruzzi P; Grossi F J Clin Med; 2019 Oct; 8(10):. PubMed ID: 31581482 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]